APPENDIX 18: RELAPSE PREVENTIONS (ADULTS) - STUDY CHARACTERISTICS TABLE

6.6.7 CONTINUED PHARMACOTHERAPY FOR RELAPSE PREVENTION

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Selective Serotonin Reuptake Inhibitors (SSRIs)												
Paroxetine												
KUMAR1999	USA	NR	35	38%	8670%	NR	28	28	Pill Placebo	N/A	7	16
							27	27	Paroxetine	0	7	16
STEIN2002b	BEL; BRA; CAN; ESP; FRA; GBR; IRL; ITA, NED, RSA	MINI (DSM-IV)	38	60%	93%	0%	161	161	Pill Placebo	N/A	7	24
							162	162	Paroxetine	36.5	7	24
Escitalopram												
MONTGOMERY2005	Multiple	ND: LSAS	37	72%	95%	0%	181	181	Pill Placebo	N/A	7	24
							191	190	Escitalopram	17.7895	7	24
Sertraline												
VAN-AMERINGEN2001	CAN	SCID (DSM-IV)	36	0.44	0.93	0	69	69	Pill Placebo	N/A	7	20
							135	134	Sertraline	146.7	7	20
Anticonvulsants												
Pregablin												
GREIST2011	USA	MINI (DSM-IV)	35	45%	80%	0%	73	72	Pill Placebo	N/A	7	26
							80	78	Pregabalin (450mg)	450	7	26